The Role of Lipids in Immune Cell Function in SLE Patients

University College, London300 enrolled

Overview

The overall aim of this project is to investigate the different types of immune cells found in the blood of patients with Systemic Lupus Erythematosus (SLE) and healthy donors. We know that the amount of fat on the surface of immune cells is an important factor controlling their behaviour. Immune cells from SLE patients are defective and this is associated with changes in the levels of fat on these cells. This project will investigate the level of fat in the blood and on immune cells from patients with SLE and age matched healthy controls, and measure how changes in the amount of fat can affect the way immune cells behave.

Accelerated atherosclerosis is a serious complication of autoimmunity including patients with both adult and juvenile onset systemic lupus erythematosus (SLE). This suggests that defects in fat levels could contribute to disease pathogenesis. The immune system in patients with SLE does not work normally. In adult patients with SLE we know that many of the immune cells involved in protecting the body from infections or cancer are over-active and actually cause disease. In young people the immune system is still developing and very little is known about what goes wrong in patients that develop juvenile-onset SLE, whether this is the same as adult disease and whether the same treatments are relevant for this group of patients. This project aims to find out whether immune cells from SLE patients with adult-onset disease have the same defects as adult patients with juvenile-onset SLE. We know that an important factor that controls immune cell behaviour is the amount of fat that they have on their surface. We also know that a change in fat on immune cells from adult patients with SLE makes them defective. This project will investigate the level of fat in the blood and in immune cells from adult patients with juvenile-onset SLE and age matched healthy controls, and measure how changes in the amount of fat can affect the way immune cells behave. We will investigate how drugs that control fat levels can help to normalize the behaviour of immune cells from SLE patients.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Lupus Erythematosus, Systemic

Interventions

Blood sampling to include Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA)OTHER

* Blood sampling to measure immune cell phenotypes and examine DNA/RNA and identify serum biomarkers. * Food Frequency Questionnaires (FFQs) and/or diet recall questionnaires to assess dietary intake. * Cardiovascular Ultrasound Scans (USS) to measure how well blood is carried around the body.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of SLE according to American College of Rheumatology revised criteria * Having given written informed consent prior to undertaking any study-related procedures. * Male and female patients between the ages of 18 and 80 years. Patients who have met all the above inclusion criteria listed and healthy donors will be screened for the following exclusion criteria: Exclusion Criteria: * Under any administrative or legal supervision. * Conditions/situations such as: * A concomitant autoimmune disease * Impossibility to meet specific protocol requirements (e.g. blood sampling). * Patient is the Investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol. * Uncooperative or any condition that could make the patient potentially non-compliant to the study procedures. * Pregnant or breast-feeding women, currently or in the last three months prior to inclusion. * Patients who have been vaccinated in the last three months prior to inclusion.

Locations (1)

University College London Hospitals NHS Foundation Trust

London, United Kingdom

RECRUITING

Outcomes

Primary Outcomes

Collection of blood samples

Blood sampling to measure immune cell phenotypes and examine DNA/RNA and identify serum biomarkers.

Time frame: 4 hours from point of sample collection

Completion of FFQ's and/or diet recall questionnaires

FFQ's and/or diet recall questionnaires to assess dietary intake

Time frame: Same day as recruited to study.

Cardiovascular Ultrasound scans (USS)

USS of Intima Media Thickness (IMT), Flow Mediated Dilatation (FMD), Pulse Wave Velocity (PWV) and Laser Doppler Flowmetry measurement. As part of the procedure, sub lingual administration of GTN spray will be administered to measure FMD.

Time frame: Within 2 months from recruitment.

Central Contacts

Liz Jury, Prof

CONTACT

02031082161 e.jury@ucl.ac.uk

George Robinson, Dr

CONTACT

02031082167 george.robinson.15@ucl.ac.uk

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.